Investors worry patients won’t make that price leap and that Hims, which has built its business on affordable healthcare, ...

Zepbound is made by drugmaker Eli Lilly. While Hims & Hers offers it for $1,899 per month, Lilly said the price on its own ...

Shares of Hims & Hers Health Inc. ended Tuesday over 5% higher, lifting retail investor mood after the telehealth company ...

The telehealth-consultation platform said it plans to continue expanding its weight loss offerings.

Telehealth firm Hims & Hers Health said on Tuesday it plans to sell Eli Lilly's weight-loss drug, as it widens its offerings ...

Eli Lilly quickly disassociated itself from Hims & Hers after the telehealth company said it was selling the pharmaceutical ...

Eli Lilly (LLY) leads with groundbreaking tirzepatide (Mounjaro/Zepbound), while Hims & Hers Health (HIMS) faces challenges.

Shares of Hims & Hers Health (HIMS) rallied on Tuesday after the telehealth company said it would begin selling branded versions of Eli ...

Hims & Hers (HIMS) stock slid Wednesday, a day after the company announced new weight-loss drug offerings — an update that ...

Hims & Hers Health shares closed up 5% on Tuesday after the company announced patients can access Eli Lilly's weight loss ...

Hims & Hers is expanding access to Eli Lilly's branded weight loss drug Zepbound and diabetes drug Mounjaro as well as ...

Hims & Hers Health (HIMS) is trying its best to stay relevant in the multi-billion dollar obesity treatment market. Despite a ...